| __timestamp | Blueprint Medicines Corporation | Geron Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 7890000 | 16758000 |
| Thursday, January 1, 2015 | 14456000 | 17793000 |
| Friday, January 1, 2016 | 19218000 | 18761000 |
| Sunday, January 1, 2017 | 27986000 | 19287000 |
| Monday, January 1, 2018 | 47928000 | 18707000 |
| Tuesday, January 1, 2019 | 96388000 | 20893000 |
| Wednesday, January 1, 2020 | 157743000 | 25678000 |
| Friday, January 1, 2021 | 195293000 | 29665000 |
| Saturday, January 1, 2022 | 237374000 | 43628000 |
| Sunday, January 1, 2023 | 295141000 | 69135000 |
| Monday, January 1, 2024 | 359272000 |
Unlocking the unknown
In the ever-evolving landscape of biotechnology, operational efficiency is paramount. Over the past decade, Blueprint Medicines Corporation and Geron Corporation have showcased contrasting trajectories in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Blueprint Medicines saw a staggering increase of over 3,600% in SG&A costs, reflecting its aggressive expansion and investment in operational infrastructure. In contrast, Geron Corporation's SG&A expenses grew by approximately 310%, indicating a more conservative approach.
By 2023, Blueprint Medicines' SG&A expenses were over four times higher than Geron's, highlighting its commitment to scaling operations. This divergence underscores the strategic differences between the two companies, with Blueprint Medicines focusing on rapid growth and Geron maintaining a steady course. As the biotech sector continues to innovate, these financial strategies will play a crucial role in shaping their future trajectories.
Who Optimizes SG&A Costs Better? AbbVie Inc. or Blueprint Medicines Corporation
Operational Costs Compared: SG&A Analysis of Merck & Co., Inc. and Geron Corporation
Bristol-Myers Squibb Company and Blueprint Medicines Corporation: SG&A Spending Patterns Compared
Comparing SG&A Expenses: Regeneron Pharmaceuticals, Inc. vs Blueprint Medicines Corporation Trends and Insights
Comparing SG&A Expenses: Intra-Cellular Therapies, Inc. vs Geron Corporation Trends and Insights
BioMarin Pharmaceutical Inc. vs Geron Corporation: SG&A Expense Trends
Breaking Down SG&A Expenses: Blueprint Medicines Corporation vs ACADIA Pharmaceuticals Inc.
SG&A Efficiency Analysis: Comparing Blueprint Medicines Corporation and PTC Therapeutics, Inc.
Blueprint Medicines Corporation and Bausch Health Companies Inc.: SG&A Spending Patterns Compared
Blueprint Medicines Corporation vs Taro Pharmaceutical Industries Ltd.: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for Veracyte, Inc. and Geron Corporation
Cost Management Insights: SG&A Expenses for MorphoSys AG and Geron Corporation